ACE2 and COVID-19: The ubiquity of the ACE2 enzyme and patient susceptibility can lead to multiorgan failure, including acute myocardial infarction and/or myocarditis and liver and kidney damage, resulting in systemic disorders.[32] The increased risk of COVID-19 in obese individuals is also explained by the wide distribution of ACE2 in small intestinal enterocytes.[33] The immune system becomes over-activated during the acute phase of infection, leading to the production of significant amounts of cytokines and chemokines.